Eris Lifesciences Q4 Review - New Launches, Cost Control Will Continue To Lead Growth: Prabhudas Lilladher
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Prabhudas Lilladher Report
We maintain our positive outlook on Eris Lifesciences Ltd., but have marginally adjusted our estimates for FY22E/23E, due to lower than expected industry growth post second wave of the pandemic.
Q4 FY21 earnings were below our estimates, while above the industry growth in its respective product segments by 2-2.5 times.
With growth in top brands and pick up in marketing activities, the company continues to outperform its peers and Indian pharma market - led by strong growth in chronic products that contribute 75-85% revenues.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.